» Articles » PMID: 28691438

HIV Viral Load As an Independent Risk Factor for Tuberculosis in South Africa: Collaborative Analysis of Cohort Studies

Overview
Journal J Int AIDS Soc
Date 2017 Jul 11
PMID 28691438
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Chronic immune activation due to ongoing HIV replication may lead to impaired immune responses against opportunistic infections such as tuberculosis (TB). We studied the role of HIV replication as a risk factor for incident TB after starting antiretroviral therapy (ART).

Methods: We included all HIV-positive adult patients (≥16 years) in care between 2000 and 2014 at three ART programmes in South Africa. Patients with previous TB were excluded. Missing CD4 cell counts and HIV-RNA viral loads at ART start (baseline) and during follow-up were imputed. We used parametric survival models to assess TB incidence (pulmonary and extrapulmonary) by CD4 cell and HIV-RNA levels, and estimated the rate ratios for TB by including age, sex, baseline viral loads, CD4 cell counts, and WHO clinical stage in the model. We also used Poisson general additive regression models with time-updated CD4 and HIV-RNA values, adjusting for age and sex.

Results: We included 44,260 patients with a median follow-up time of 2.7 years (interquartile range [IQR] 1.0-5.0); 3,819 incident TB cases were recorded (8.6%). At baseline, the median age was 34 years (IQR 28-41); 30,675 patients (69.3%) were female. The median CD4 cell count was 156 cells/µL (IQR 79-229) and the median HIV-RNA viral load 58,000 copies/mL (IQR 6,000-240,000). Overall TB incidence was 26.2/1,000 person-years (95% confidence interval [CI] 25.3-27.0). Compared to the lowest viral load category (0-999 copies/mL), the adjusted rate ratio for TB was 1.41 (95% CI 1.15-1.75,  < 0.001) in the highest group (>10,000 copies/mL). Time-updated analyses for CD4/HIV-RNA confirmed the association of viral load with the risk for TB.

Conclusions: Our results indicate that ongoing HIV replication is an important risk factor for TB, regardless of CD4 cell counts, and underline the importance of early ART start and retention on ART.

Citing Articles

HIV replication and tuberculosis risk among people living with HIV in Europe: A multicohort analysis, 1983-2015.

Atkinson A, Kraus D, Banholzer N, Miro J, Reiss P, Kirk O PLoS One. 2024; 19(10):e0312035.

PMID: 39453919 PMC: 11508122. DOI: 10.1371/journal.pone.0312035.


Genetic Diversity of Strains Isolated from HIV-Infected Patients in Mexico.

Valencia-Trujillo D, Avila-Trejo A, Garcia-Reyes R, Narvaez-Diaz L, Segura Del Pilar M, Mujica-Sanchez M Pathogens. 2024; 13(5).

PMID: 38787280 PMC: 11124049. DOI: 10.3390/pathogens13050428.


Monocyte to Lymphocyte ratio is highly specific in diagnosing latent tuberculosis and declines significantly following tuberculosis preventive therapy: A cross-sectional and nested prospective observational study.

Mayito J, Meya D, Miriam A, Dhikusooka F, Rhein J, Sekaggya-Wiltshire C PLoS One. 2023; 18(11):e0291834.

PMID: 38033005 PMC: 10688757. DOI: 10.1371/journal.pone.0291834.


Bayesian parametric modeling of time to tuberculosis co-infection of HIV/AIDS patients at Jimma Medical Center, Ethiopia.

Umeta A, Yermosa S, Dufera A Sci Rep. 2022; 12(1):16475.

PMID: 36182998 PMC: 9526740. DOI: 10.1038/s41598-022-20872-7.


Predictors for tuberculosis co-infection in people living with HIV/AIDs.

Zerdali E, Yilmaz Nakir I, Surme S, Sayili U, Yildirim M Afr Health Sci. 2022; 21(3):995-1002.

PMID: 35222560 PMC: 8843284. DOI: 10.4314/ahs.v21i3.6.


References
1.
Madhi S, Nachman S, Violari A, Kim S, Cotton M, Bobat R . Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med. 2011; 365(1):21-31. PMC: 3164539. DOI: 10.1056/NEJMoa1011214. View

2.
Mocroft A, Reiss P, Kirk O, Mussini C, Girardi E, Morlat P . Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?. Clin Infect Dis. 2010; 51(5):611-9. DOI: 10.1086/655761. View

3.
Lodi S, Del Amo J, Monforte A, Abgrall S, Sabin C, Morrison C . Risk of tuberculosis following HIV seroconversion in high-income countries. Thorax. 2012; 68(3):207-13. DOI: 10.1136/thoraxjnl-2012-201740. View

4.
Corbett E, Churchyard G, Charalambos S, Samb B, Moloi V, Clayton T . Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis. 2002; 34(9):1251-8. DOI: 10.1086/339540. View

5.
Charles M, Lindegren M, Wester C, Blevins M, Sterling T, Dung N . Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries. PLoS One. 2016; 11(4):e0153243. PMC: 4830552. DOI: 10.1371/journal.pone.0153243. View